FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2157-2159 November 27, 2003 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schreiber, M. D. PubMed Citation

The past three decades have seen the emergence of neonatology as a vibrant subspecialty of pediatrics, highlighted by advances in the management of the respiratory distress syndrome in preterm infants. It is now widely accepted that surfactant deficiency is the biologic basis for neonatal respiratory distress syndrome and that a combination of antenatal corticosteroids, postnatal surfactant therapy, and effective ventilatory assistance is key to successful management. Historically, pulmonary ischemia was thought to be an underlying physiological mechanism for neonatal respiratory distress syndrome; it is now clear that residual fetal pulmonary hypertension, with resultant shunting of deoxygenated blood away from the . . . [Full Text of this Article]

Source Information

From Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland.

This article has been cited by other articles:

• Field, D., Elbourne, D., Truesdale, A., Grieve, R., Hardy, P., Fenton, A.C., Subhedar, N., Ahluwalia, J., Halliday, H.L., Stocks, J., Tomlin, K., Normand, C., on behalf of the INNOVO Trial Collaborating Group, (2005). Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: The INNOVO Multicentre Randomised Controlled Trial (ISRCTN 17821339). Pediatrics 115: 926-936 [Abstract] [Full Text]